Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG) is one of Tuesday’s top-performing stocks.
If you want to invest in EyeGate Pharma, or if you simply want to find out more about the company and why it is rising in value, this is the article for you. Read on to find out all of the key information you need to know about the company and its stock.
To buy shares in EyeGate Pharma quickly, easily and affordably, check out the two options in the section below. They are the best places to buy EyeGate Pharmaceuticals stock online:
How & where to buy EyeGate Pharma stock
To buy EyeGate Pharma shares, simply click on one of the links below, fund your newly created account, then search for the company’s ticker, EYEG. Then, you can enter the number of EYEG shares you want to buy and execute your transaction.
Here are the two best platforms to buy, sell and trade EYEG stock today thanks to their low fees and reliable user interfaces:
eToro is one of the world's leading multi-asset trading platforms offering some of the lowest commission and fee rates in the industry. It's social copy trading features make it a great choice for those getting started.
Financial company driven by technology and offering all-in-one self-directed investment platform that provides excellent user experience.
What is EyeGate Pharmaceuticals?
Incorporated in 1998 and based in Waltham, Massachusetts, it is a clinical-stage pharmaceutical company.
EyeGate is focussed on developing and commercialising products for treating inflammatory and immune diseases with a focus on (you guessed it) the eye and nervous system in the United States.
The price of EyeGate stock surged in after-hours trading on Monday after the company announced it entered a non-binding letter of intent to acquire Bayon Therapeutics for around $7.1 million.
Should I buy EyeGate Pharma stock today?
Investing always carries risk, and this is heightened with pharmaceutical companies because of the lengthy testing process and stringent regulations that any potential product needs to pass through before achieving commercialisation.
However, if you have looked in detail at any of EyeGate’s treatment candidates and the company’s business model, and you have determined there is the potential for substantial growth, investing now could be a smart move ahead of share price accretion.
EyeGate Pharmaceuticals price target 2021
Our EyeGate Pharma share price forecast is as follows: a 12-month high of $15, with a median of $14 and a low of $13.25.